Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Notes Payables (2016 - 2022)

IGC Pharma (IGC) has disclosed Notes Payables for 11 consecutive years, with $3000.0 as the latest value for Q2 2022.

  • Quarterly Notes Payables changed 0.0% to $3000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Jun 2022, changed 0.0% year-over-year, with the annual reading at $3000.0 for FY2022, 99.01% down from the prior year.
  • Notes Payables for Q2 2022 was $3000.0 at IGC Pharma, roughly flat from $3000.0 in the prior quarter.
  • The five-year high for Notes Payables was $1.8 million in Q2 2018, with the low at $3000.0 in Q2 2021.
  • Average Notes Payables over 5 years is $307800.0, with a median of $50000.0 recorded in 2019.
  • The sharpest move saw Notes Payables soared 508.0% in 2021, then crashed 99.01% in 2022.
  • Over 5 years, Notes Payables stood at $1.8 million in 2018, then plummeted by 97.22% to $50000.0 in 2019, then skyrocketed by 404.0% to $252000.0 in 2020, then tumbled by 98.81% to $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022.
  • According to Business Quant data, Notes Payables over the past three periods came in at $3000.0, $3000.0, and $3000.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.